{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T17:54:59Z","timestamp":1791050099695,"version":"4.1.0"},"reference-count":79,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,9,22]],"date-time":"2022-09-22T00:00:00Z","timestamp":1663804800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100016747","name":"Mercer University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016747","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmacological Sciences"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1016\/j.jphs.2022.09.004","type":"journal-article","created":{"date-parts":[[2022,9,24]],"date-time":"2022-09-24T00:59:28Z","timestamp":1663981168000},"page":"211-222","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["Mechanism of canagliflozin-induced vasodilation in resistance mesenteric arteries and the regulation of systemic blood pressure"],"prefix":"10.1016","volume":"150","author":[{"given":"Ahasanul","family":"Hasan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farzana","family":"Zerin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sreelakshmi N.","family":"Menon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Md. Ashraful","family":"Alam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6897-2901","authenticated-orcid":false,"given":"Raquibul","family":"Hasan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.jphs.2022.09.004_bib1","doi-asserted-by":"crossref","first-page":"72","DOI":"10.3810\/hp.2013.04.1020","article-title":"Efficacy and safety of canagliflozin treatment in older subjects with type 2 diabetes mellitus: a randomized trial","volume":"41","author":"Bode","year":"2013","journal-title":"Hosp Pract"},{"key":"10.1016\/j.jphs.2022.09.004_bib2","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1016\/S0140-6736(13)60683-2","article-title":"Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial","volume":"382","author":"Cefalu","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.jphs.2022.09.004_bib3","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1111\/dom.12273","article-title":"Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes on background metformin and pioglitazone","volume":"16","author":"Forst","year":"2014","journal-title":"Diabetes Obes Metabol"},{"key":"10.1016\/j.jphs.2022.09.004_bib4","doi-asserted-by":"crossref","first-page":"2582","DOI":"10.1007\/s00125-013-3039-1","article-title":"Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomised trial","volume":"56","author":"Lavalle-Gonzalez","year":"2013","journal-title":"Diabetologia"},{"key":"10.1016\/j.jphs.2022.09.004_bib5","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.2337\/dc11-1926","article-title":"Dose-ranging effects of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to metformin in subjects with type 2 diabetes","volume":"35","author":"Rosenstock","year":"2012","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jphs.2022.09.004_bib6","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1111\/dom.12054","article-title":"Efficacy and safety of \u20ac canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise","volume":"15","author":"Stenl\u00f6f","year":"2013","journal-title":"Diabetes Obes Metabol"},{"key":"10.1016\/j.jphs.2022.09.004_bib7","doi-asserted-by":"crossref","first-page":"2508","DOI":"10.2337\/dc12-2491","article-title":"Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea: a 52-week, randomized trial","volume":"36","author":"Schernthaner","year":"2013","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jphs.2022.09.004_bib8","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1111\/ijcp.12322","article-title":"Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sulphonylurea: a randomised trial","volume":"67","author":"Wilding","year":"2013","journal-title":"Int J Clin Pract"},{"key":"10.1016\/j.jphs.2022.09.004_bib9","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1111\/dom.12090","article-title":"Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease","volume":"15","author":"Yale","year":"2013","journal-title":"Diabetes Obes Metabol"},{"issue":"2","key":"10.1016\/j.jphs.2022.09.004_bib10","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1038\/s41371-019-0268-x","article-title":"Hypertension and type 2 diabetes: lights and shadows about causality","volume":"34","author":"Colussi","year":"2020","journal-title":"J\u00a0Hum Hypertens"},{"issue":"5","key":"10.1016\/j.jphs.2022.09.004_bib11","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1161\/01.HYP.0000125726.92964.ab","article-title":"Adverse prognostic significance of new diabetes in treated hypertensive subjects","volume":"43","author":"Verdecchia","year":"2004","journal-title":"Hypertension"},{"issue":"9","key":"10.1016\/j.jphs.2022.09.004_bib12","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1038\/hr.2017.67","article-title":"Hypertension with diabetes mellitus: significance from an epidemiological perspective for Japanese","volume":"40","author":"Tatsumi","year":"2017","journal-title":"Hypertens Res"},{"issue":"2","key":"10.1016\/j.jphs.2022.09.004_bib13","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1093\/eurheartj\/ehz486","article-title":"ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD","volume":"41","author":"Cosentino","year":"2019","journal-title":"Eur Heart J"},{"issue":"19","key":"10.1016\/j.jphs.2022.09.004_bib14","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1093\/eurheartj\/ehv728","article-title":"Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME\u00ae trial","volume":"37","author":"Fitchett","year":"2016","journal-title":"Eur Heart J"},{"issue":"6","key":"10.1016\/j.jphs.2022.09.004_bib15","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/j.jacbts.2020.02.004","article-title":"Mechanisms of cardiovascular benefits of sodium glucose Co-transporter 2 (SGLT2) inhibitors: a state-of-the-art review","volume":"5","author":"Lopaschuk","year":"2020","journal-title":"JACC Basic Transl Sci"},{"issue":"21","key":"10.1016\/j.jphs.2022.09.004_bib16","first-page":"2099","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1016\/j.jphs.2022.09.004_bib17","doi-asserted-by":"crossref","first-page":"181","DOI":"10.3810\/pgm.2013.05.2667","article-title":"Effects of dapagliflozin on cardiovascular risk factors","volume":"125","author":"Ptaszynska","year":"2013","journal-title":"Postgrad Med"},{"issue":"5","key":"10.1016\/j.jphs.2022.09.004_bib18","doi-asserted-by":"crossref","first-page":"e019463","DOI":"10.1161\/JAHA.120.019463","article-title":"Effects of sodium\/glucose cotransporter 2 (SGLT2) inhibitors on cardiovascular and metabolic outcomes in patients without diabetes mellitus: a systematic review and meta-analysis of randomized-controlled trials","volume":"10","author":"Teo","year":"2021","journal-title":"J\u00a0Am Heart Assoc"},{"issue":"3","key":"10.1016\/j.jphs.2022.09.004_bib19","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/S2213-8587(15)00417-9","article-title":"Blood pressure and glycaemic effects of dapagliflozin versus placebo in patients with type 2 diabetes on combination antihypertensive therapy: a randomised, double-blind, placebo-controlled, phase 3 study","volume":"4","author":"Weber","year":"2016","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"22","key":"10.1016\/j.jphs.2022.09.004_bib20","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"10.1016\/j.jphs.2022.09.004_bib21","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1093\/ajh\/hpy025","article-title":"Diabetes and hypertension: clinical update","volume":"31","author":"Khangura","year":"2018","journal-title":"Am J Hypertens"},{"key":"10.1016\/j.jphs.2022.09.004_bib22","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.lfs.2018.01.032","article-title":"The anti-diabetic drug dapagliflozin induces vasodilation via activation of PKG and Kv channels","volume":"197","author":"Li","year":"2018","journal-title":"Life Sci"},{"key":"10.1016\/j.jphs.2022.09.004_bib23","doi-asserted-by":"crossref","first-page":"115153","DOI":"10.1016\/j.taap.2020.115153","article-title":"Empagliflozin dilates the rabbit aorta by activating PKG and voltage-dependent K+ channels","volume":"403","author":"Seo","year":"2020","journal-title":"Toxicol Appl Pharmacol"},{"issue":"19","key":"10.1016\/j.jphs.2022.09.004_bib24","doi-asserted-by":"crossref","first-page":"10842","DOI":"10.3390\/ijms221910842","article-title":"Empagliflozin relaxes resistance mesenteric arteries by stimulating multiple smooth muscle cell voltage-gated K+ (KV) channels","volume":"22","author":"Hasan","year":"2021","journal-title":"Int J Mol Sci"},{"issue":"2","key":"10.1016\/j.jphs.2022.09.004_bib25","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1161\/HYPERTENSIONAHA.120.16466","article-title":"Mechanisms of SGLT2 (Sodium-Glucose transporter type 2) inhibition-induced relaxation in arteries from human visceral adipose tissue","volume":"77","author":"De Stefano","year":"2021","journal-title":"Hypertension"},{"issue":"1","key":"10.1016\/j.jphs.2022.09.004_bib26","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1186\/s12967-019-1881-8","article-title":"Acute canagliflozin treatment protects against in\u00a0vivo myocardial ischemia-reperfusion injury in non-diabetic male rats and enhances endothelium-dependent vasorelaxation","volume":"17","author":"Sayour","year":"2019","journal-title":"J\u00a0Transl Med"},{"key":"10.1016\/j.jphs.2022.09.004_bib27","doi-asserted-by":"crossref","first-page":"113677","DOI":"10.1016\/j.bcp.2019.113677","article-title":"Empagliflozin reduces the levels of CD36 and cardiotoxic lipids while improving autophagy in the hearts of Zucker diabetic fatty rats","volume":"170","author":"Arag\u00f3n-Herrera","year":"2019","journal-title":"Biochem Pharmacol"},{"issue":"2","key":"10.1016\/j.jphs.2022.09.004_bib28","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1007\/s00125-016-4158-2","article-title":"The beneficial effects of empagliflozin, an SGLT2 inhibitor, on atherosclerosis in ApoE (-\/-) mice fed a western diet","volume":"60","author":"Han","year":"2017","journal-title":"Diabetologia"},{"issue":"1","key":"10.1016\/j.jphs.2022.09.004_bib29","doi-asserted-by":"crossref","first-page":"14659","DOI":"10.1038\/s41598-020-71599-2","article-title":"Canagliflozin ameliorates renal oxidative stress and inflammation by stimulating AMPK-Akt-eNOS pathway in the isoprenaline-induced oxidative stress model","volume":"10","author":"Hasan","year":"2020","journal-title":"Sci Rep"},{"issue":"1","key":"10.1016\/j.jphs.2022.09.004_bib30","doi-asserted-by":"crossref","first-page":"14459","DOI":"10.1038\/s41598-020-71449-1","article-title":"Canagliflozin attenuates isoprenaline-induced cardiac oxidative stress by stimulating multiple antioxidant and anti-inflammatory signaling pathways","volume":"10","author":"Hasan","year":"2020","journal-title":"Sci Rep"},{"issue":"52","key":"10.1016\/j.jphs.2022.09.004_bib31","doi-asserted-by":"crossref","first-page":"27095","DOI":"10.1073\/pnas.1917264116","article-title":"SUMO1 modification of PKD2 channels regulates arterial contractility","volume":"116","author":"Hasan","year":"2019","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"10.1016\/j.jphs.2022.09.004_bib32","first-page":"101","article-title":"Potential mechanisms responsible for cardioprotective effects of sodium-glucose co-transporter 2 inhibitors. Cardiovasc","volume":"17","author":"Lahnwong","year":"2018","journal-title":"Diabetologia"},{"issue":"1","key":"10.1016\/j.jphs.2022.09.004_bib33","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1186\/s12933-018-0749-1","article-title":"Canagliflozin attenuates the progression of atherosclerosis and inflammation process in APOE knockout mice","volume":"17","author":"Nasiri-Ansari","year":"2018","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.jphs.2022.09.004_bib34","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.redox.2017.06.009","article-title":"The SGLT2 inhibitor empagliflozin improves the primary diabetic complications in ZDF rats","volume":"13","author":"Steven","year":"2017","journal-title":"Redox Biol"},{"key":"10.1016\/j.jphs.2022.09.004_bib35","article-title":"Correction: intravascular flow stimulates PKD2 (polycystin-2) channels in endothelial cells to reduce blood pressure","volume":"9","author":"MacKay","year":"2020","journal-title":"Elife"},{"key":"10.1016\/j.jphs.2022.09.004_bib36","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.42628","article-title":"Arterial smooth muscle cell PKD2 (TRPP1) channels regulate systemic blood pressure","volume":"7","author":"Bulley","year":"2018","journal-title":"Elife"},{"issue":"390","key":"10.1016\/j.jphs.2022.09.004_bib37","doi-asserted-by":"crossref","first-page":"ra83","DOI":"10.1126\/scisignal.aac5128","article-title":"Intravascular pressure enhances the abundance of functional Kv1.5 channels at the surface of arterial smooth muscle cells","volume":"8","author":"Kidd","year":"2015","journal-title":"Sci Signal"},{"issue":"5","key":"10.1016\/j.jphs.2022.09.004_bib38","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1161\/01.HYP.25.5.1111","article-title":"A\u00a0noninvasive computerized tail-cuff system for measuring blood pressure in mice","volume":"25","author":"Krege","year":"1995","journal-title":"Hypertension"},{"issue":"5","key":"10.1016\/j.jphs.2022.09.004_bib39","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1124\/dmd.113.056440","article-title":"Metabolism and excretion of canagliflozin in mice, rats, dogs, and humans","volume":"42","author":"Mamidi","year":"2014","journal-title":"Drug Metab Dispos"},{"issue":"4","key":"10.1016\/j.jphs.2022.09.004_bib40","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.jphs.2015.03.006","article-title":"The effect of combined treatment with canagliflozin and teneligliptin on glucose intolerance in Zucker diabetic fatty rats","volume":"127","author":"Oguma","year":"2015","journal-title":"J\u00a0Pharmacol Sci"},{"issue":"2","key":"10.1016\/j.jphs.2022.09.004_bib41","first-page":"2548","article-title":"Comparative study on the cardiovascular and pancreatic effects of canagliflozin versus vildagliptin on experimentally induced diabetes and hypertension in male albino rats","volume":"8","author":"Tarteel","year":"2021","journal-title":"Eur J Mol Clin Med"},{"issue":"7","key":"10.1016\/j.jphs.2022.09.004_bib42","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1016\/j.clinthera.2015.04.015","article-title":"Pharmacokinetics, pharmacodynamics, and safety of single-dose canagliflozin in healthy Chinese subjects","volume":"37","author":"Chen","year":"2015","journal-title":"Clin Therapeut"},{"issue":"2","key":"10.1016\/j.jphs.2022.09.004_bib43","first-page":"27","article-title":"A\u00a0simple practice guide for dose conversion between animals and human","volume":"7","author":"Nair","year":"2016","journal-title":"J\u00a0Basic Clin Pharm"},{"issue":"10","key":"10.1016\/j.jphs.2022.09.004_bib44","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1007\/s40262-015-0285-z","article-title":"Clinical pharmacokinetic, pharmacodynamic, and drug-drug interaction profile of canagliflozin, a sodium-glucose Co-transporter 2 inhibitor","volume":"54","author":"Devineni","year":"2015","journal-title":"Clin Pharmacokinet"},{"issue":"6","key":"10.1016\/j.jphs.2022.09.004_bib45","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1002\/jcph.88","article-title":"Pharmacokinetics and pharmacodynamics of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in subjects with type 2 diabetes mellitus","volume":"53","author":"Devineni","year":"2013","journal-title":"J\u00a0Clin Pharmacol"},{"issue":"8","key":"10.1016\/j.jphs.2022.09.004_bib46","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1007\/s12325-015-0234-0","article-title":"Pharmacokinetics, pharmacodynamics, and safety of canagliflozin in Japanese patients with type 2 diabetes mellitus","volume":"32","author":"Iijima","year":"2015","journal-title":"Adv Ther"},{"issue":"3","key":"10.1016\/j.jphs.2022.09.004_bib47","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1124\/pr.110.002907","article-title":"cGMP-dependent protein kinases and cGMP phosphodiesterases in nitric oxide and cGMP action","volume":"62","author":"Francis","year":"2010","journal-title":"Pharmacol Rev"},{"issue":"10","key":"10.1016\/j.jphs.2022.09.004_bib48","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1042\/CS20110259","article-title":"Acute simvastatin increases endothelial nitric oxide synthase phosphorylation via AMP-activated protein kinase and reduces contractility of isolated rat mesenteric resistance arteries","volume":"121","author":"Rossoni","year":"2011","journal-title":"Clin Sci"},{"issue":"3","key":"10.1016\/j.jphs.2022.09.004_bib49","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1124\/pr.111.004770","article-title":"Molecular mechanisms regulating the vascular prostacyclin pathways and their adaptation during pregnancy and in the newborn","volume":"64","author":"Majed","year":"2012","journal-title":"Pharmacol Rev"},{"issue":"2","key":"10.1016\/j.jphs.2022.09.004_bib50","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1007\/BF03168239","article-title":"Chronic ouabain treatment increases the contribution of nitric oxide to endothelium-dependent relaxation","volume":"64","author":"Aras-L\u00f3pez","year":"2008","journal-title":"J\u00a0Physiol Biochem"},{"issue":"2","key":"10.1016\/j.jphs.2022.09.004_bib51","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1161\/01.RES.80.2.189","article-title":"In\u00a0vitro modulation of a resistance artery diameter by the tissue renin-angiotensin system of a large donor artery","volume":"80","author":"Henrion","year":"1997","journal-title":"Circ Res"},{"issue":"2","key":"10.1016\/j.jphs.2022.09.004_bib52","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1002\/j.2040-4603.2017.tb00747.x","article-title":"Smooth muscle ion channels and regulation of vascular tone in resistance arteries and arterioles","volume":"7","author":"Tykocki","year":"2017","journal-title":"Compr Physiol"},{"key":"10.1016\/j.jphs.2022.09.004_bib53","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1111\/fcp.12461","article-title":"Potassium channels in vascular smooth muscle: a pathophysiological and pharmacological perspective","volume":"33","author":"Dogan","year":"2019","journal-title":"Fundam Clin Pharmacol"},{"issue":"1","key":"10.1016\/j.jphs.2022.09.004_bib54","doi-asserted-by":"crossref","DOI":"10.1111\/micc.12418","article-title":"Channel trafficking and control of vascular tone","volume":"25","author":"Hasan","year":"2018","journal-title":"Microcirculation"},{"issue":"1","key":"10.1016\/j.jphs.2022.09.004_bib55","doi-asserted-by":"crossref","DOI":"10.1111\/micc.12421","article-title":"(V) channels and the regulation of vascular smooth muscle tone","volume":"25","author":"Jackson","year":"2018","journal-title":"Microcirculation"},{"key":"10.1016\/j.jphs.2022.09.004_bib56","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1111\/j.1476-5381.2010.01027.x","article-title":"Expression and function of the K+ channel KCNQ genes in human arteries","volume":"162","author":"Ng","year":"2011","journal-title":"Br J Pharmacol"},{"issue":"5","key":"10.1016\/j.jphs.2022.09.004_bib57","first-page":"G1055","article-title":"Expression of voltage-dependent K(+) channel genes in mesenteric artery smooth muscle cells","volume":"277","author":"Xu","year":"1999","journal-title":"Am J Physiol"},{"issue":"1","key":"10.1016\/j.jphs.2022.09.004_bib58","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.cardiores.2003.12.026","article-title":"Pharmacology of cardiac potassium channels","volume":"62","author":"Tamargo","year":"2004","journal-title":"Cardiovasc Res"},{"issue":"1","key":"10.1016\/j.jphs.2022.09.004_bib59","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/S0006-8993(00)02469-0","article-title":"4-aminopyridine, a specific blocker of K(+) channels, inhibited inward Na(+) current in rat cerebellar granule cells","volume":"873","author":"Mei","year":"2000","journal-title":"Brain Res"},{"issue":"6","key":"10.1016\/j.jphs.2022.09.004_bib60","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1124\/mol.65.6.1364","article-title":"Kv1.3-blocking 5-phenylalkoxypsoralens: a new class of immunomodulators","volume":"65","author":"Vennekamp","year":"2004","journal-title":"Mol Pharmacol"},{"issue":"2","key":"10.1016\/j.jphs.2022.09.004_bib61","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1540\/jsmr.44.65","article-title":"Physiological roles of K+ channels in vascular smooth muscle cells","volume":"44","author":"Ko","year":"2008","journal-title":"J\u00a0Smooth Muscle Res"},{"issue":"5","key":"10.1016\/j.jphs.2022.09.004_bib62","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1085\/jgp.201411259","article-title":"Paxilline inhibits BK channels by an almost exclusively closed-channel block mechanism","volume":"144","author":"Zhou","year":"2014","journal-title":"J\u00a0Gen Physiol"},{"issue":"3","key":"10.1016\/j.jphs.2022.09.004_bib63","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1211\/0022357022755","article-title":"Blocking actions of glibenclamide on ATP-sensitive K+ channels in pig urethral myocytes","volume":"56","author":"Teramoto","year":"2004","journal-title":"J\u00a0Pharm Pharmacol"},{"issue":"1","key":"10.1016\/j.jphs.2022.09.004_bib64","doi-asserted-by":"crossref","first-page":"39","DOI":"10.33549\/physiolres.932780","article-title":"Lisinopril alters contribution of nitric oxide and K(Ca) channels to vasodilatation in small mesenteric arteries of spontaneously hypertensive rats","volume":"64","author":"Albarwani","year":"2015","journal-title":"Physiol Res"},{"key":"10.1016\/j.jphs.2022.09.004_bib65","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1152\/physiol.00040.2005","article-title":"Calcium-activated potassium channels and the regulation of vascular tone","volume":"21","author":"Ledoux","year":"2006","journal-title":"Physiology"},{"key":"10.1016\/j.jphs.2022.09.004_bib66","doi-asserted-by":"crossref","first-page":"120101","DOI":"10.1016\/j.lfs.2021.120101","article-title":"Mechanisms underlying the vasodilatory effects of canagliflozin in the rabbit thoracic aorta: involvement of the SERCA pump and Kv channels","volume":"287","author":"Seo","year":"2021","journal-title":"Life Sci"},{"issue":"3","key":"10.1016\/j.jphs.2022.09.004_bib67","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1113\/jphysiol.2001.013105","article-title":"Propionate-induced relaxation in rat mesenteric arteries: a role for endothelium-derived hyperpolarising factor","volume":"538","author":"Knock","year":"2002","journal-title":"J\u00a0Physiol"},{"issue":"10","key":"10.1016\/j.jphs.2022.09.004_bib68","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1124\/dmd.111.040048","article-title":"Pharmacokinetic and pharmacodynamic modeling of the effect of an sodium-glucose cotransporter inhibitor, phlorizin, on renal glucose transport in rats","volume":"39","author":"Yamaguchi","year":"2011","journal-title":"Drug Metab Dispos"},{"issue":"5","key":"10.1016\/j.jphs.2022.09.004_bib69","doi-asserted-by":"crossref","first-page":"e12948","DOI":"10.1111\/ijcp.12948","article-title":"Effects of canagliflozin on cardiovascular risk factors in patients with type 2 diabetes mellitus","volume":"71","author":"Budoff","year":"2017","journal-title":"Int J Clin Pract"},{"issue":"2","key":"10.1016\/j.jphs.2022.09.004_bib70","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1093\/cvr\/cvy295","article-title":"Potential mechanisms underlying the cardiovascular benefits of sodium glucose cotransporter 2 inhibitors: a systematic review of data from preclinical studies","volume":"115","author":"Chin","year":"2019","journal-title":"Cardiovasc Res"},{"issue":"18","key":"10.1016\/j.jphs.2022.09.004_bib71","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1161\/CIRCULATIONAHA.120.048740","article-title":"Blood pressure effects of canagliflozin and clinical outcomes in type 2 diabetes and chronic kidney disease: insights from the CREDENCE trial","volume":"143","author":"Ye","year":"2021","journal-title":"Circulation"},{"issue":"9","key":"10.1016\/j.jphs.2022.09.004_bib72","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1161\/CIRCULATIONAHA.119.042007","article-title":"Canagliflozin and cardiovascular and renal outcomes in type 2 diabetes mellitus and chronic kidney disease in primary and secondary cardiovascular prevention groups","volume":"140","author":"Mahaffey","year":"2019","journal-title":"Circulation"},{"issue":"15","key":"10.1016\/j.jphs.2022.09.004_bib73","doi-asserted-by":"crossref","first-page":"7774","DOI":"10.3390\/ijms22157774","article-title":"The sodium-glucose cotransporter-2 inhibitor canagliflozin alleviates endothelial dysfunction following in\u00a0vitro vascular ischemia\/reperfusion injury in rats","volume":"22","author":"Korkmaz-Ic\u00f6z","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jphs.2022.09.004_bib74","doi-asserted-by":"crossref","DOI":"10.1093\/eurheartj\/ehz747.0327","article-title":"P722 Glycemic control with canagliflozin, a SGLT-2 inhibitor, attenuates atherosclerosis and endothelial dysfunction in diabetic apolipoprotein e-deficient mice","volume":"40","author":"Rahadian","year":"2019","journal-title":"Eur Heart J"},{"issue":"11","key":"10.1016\/j.jphs.2022.09.004_bib75","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.5551\/jat.52100","article-title":"Canagliflozin prevents diabetes-induced vascular dysfunction in ApoE-deficient mice","volume":"27","author":"Rahadian","year":"2020","journal-title":"J\u00a0Atherosclerosis Thromb"},{"key":"10.1016\/j.jphs.2022.09.004_bib76","first-page":"1232583","article-title":"Effects of newer antidiabetic drugs on endothelial function and arterial stiffness: a systematic review and meta-analysis","author":"Batzias","year":"2018","journal-title":"J\u00a0Diabetes Res"},{"issue":"2","key":"10.1016\/j.jphs.2022.09.004_bib77","doi-asserted-by":"crossref","first-page":"233","DOI":"10.2174\/18756212MTA1aMzIwy","article-title":"Diabetes mellitus, arterial stiffness and cardiovascular disease: clinical implications and the influence of SGLT2i","volume":"19","author":"Lamacchia","year":"2021","journal-title":"Curr Vasc Pharmacol"},{"issue":"1","key":"10.1016\/j.jphs.2022.09.004_bib78","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/s12933-017-0511-0","article-title":"Effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, on blood pressure and markers of arterial stiffness in patients with type 2 diabetes mellitus: a post hoc analysis","volume":"16","author":"Pfeifer","year":"2017","journal-title":"Cardiovasc Diabetol"},{"issue":"1","key":"10.1016\/j.jphs.2022.09.004_bib79","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1186\/s12933-019-0877-2","article-title":"Canagliflozin for Japanese patients with chronic heart failure and type II diabetes","volume":"18","author":"Sezai","year":"2019","journal-title":"Cardiovasc Diabetol"}],"container-title":["Journal of Pharmacological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1347861322000718?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1347861322000718?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T20:02:19Z","timestamp":1761163339000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1347861322000718"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":79,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["S1347861322000718"],"URL":"https:\/\/doi.org\/10.1016\/j.jphs.2022.09.004","relation":{},"ISSN":["1347-8613"],"issn-type":[{"value":"1347-8613","type":"print"}],"subject":[],"published":{"date-parts":[[2022,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Mechanism of canagliflozin-induced vasodilation in resistance mesenteric arteries and the regulation of systemic blood pressure","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmacological Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jphs.2022.09.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Production and hosting by Elsevier B.V. on behalf of Japanese Pharmacological Society.","name":"copyright","label":"Copyright"}]}}